,
Martin Bergstrand, MSc, PhD student
---
Division of Pharmacokinetics and Drug Therapy,
Department of Pharmaceutical Biosciences,
Uppsala University
---
P.O. Box 591
SE-751 24 Uppsala
Sweden
Dear Johan and Anna,
I answered to a similar question about a year ago. You can find that thread
via this link:
http://www.cognigencorp.com/nonmem/current/2007-July/0282.html.
Kind regards,
Martin
-Original Message-
From: [EMAIL PROTECTED] [mailto:[EMAIL PROTECTED] On
Behalf Of Rosenbo
ield similar or faster runtimes.
Kind regards,
Martin Bergstrand & Joakim Nyberg, PhD students
---
Division of Pharmacokinetics and Drug Therapy,
Department of Pharmaceutical Biosciences,
Uppsala University
ation.
Best regards,
Martin
_
From: Matt Hutmacher [mailto:[EMAIL PROTECTED]
Sent: den 4 december 2008 22:28
To: 'Matt Hutmacher'; 'Martin Bergstrand'; nmusers@globomaxnm.com
Cc: 'Joakim Nyberg'
Subject: RE: [NMusers] Lapacian estimation without second de
Dear all,
PsN is useful tool for this purpose but I think that the functionality that
should be used is called "Stochastic Simulation and Estimation (SSE)". The
Bootstrap functionality is primarily used for obtaining parameter
uncertainties. A detailed userguide for the SSE functionality is
users archive.
See for example the answer from Mats Karlsson in this thread
(http://nonmem.org/nonmem/nm/98apr032002.html).
Kind regards,
Martin Bergstrand, MSc, PhD student
---
Department of Pharmaceutical Biosciences,
Uppsala Unive
e has its drawbacks. Especially so since it is often
applied to bioanalytical data for which non-random censoring of estimated
negative concentrations is performed.
Kind regards,
Martin Bergstrand, Andrew Hooker and Joakim Nyberg
)/(F+M))**2)
RES = DV - IPRED
IWRES = RES/W
Y = Y = LOG(F+M) + W * ERR(1)
$SIGMA 1 FIX
Question to Kelong Han: Do you estimate M or do you set this parameter to a
fix value?
Kind regards,
Martin Bergstrand, MSc, PhD student
---
Department of
;---
-
I hope this is of some help to you.
Kind regards,
Martin Bergstrand, MSc, PhD student
---
Division of Pharmacokinetics and Drug Therapy,
Department of Pharmaceutical Biosciences
time that VOM is set to 1 you can
calculate the average fraction of the remaining drug substance in the depot
compartment that is lost.
I hope that this is of some use to you.
Kind regards,
Martin Bergstrand, MSc, PhD student
---
Department of Pharmaceut
...@globomaxnm.com] On
Behalf Of Martin Bergstrand
Sent: den 27 augusti 2009 11:13
To: 'Seng Kok Yong'; 'Nick Holford'; 'nmusers'
Subject: RE: [NMusers] PK data from individuals who vomited after drug
ingestion
Dear Kok-Yong Seng,
With my naive thinking what happens
page abstract
regarding that poster is available already now via the ACoP webpage
(http://www.go-acop.org/acop2009/posters - Title: "Prediction Corrected
Visual Predictive Checks" Authors: Martin Bergstrand, Andrew C. Hooker,
Johan E. Wallin, Mats O. Karlsson). Please have a look at th
distribution errors ... Comets E,
Brendel K, Mentré F. CMPB. 2008
_
From: Martin Bergstrand [mailto:martin.bergstr...@farmbio.uu.se]
Sent: den 20 september 2009 19:32
To: 'Leonid Gibiansky'; 'Nick Holford'
Cc: 'Dider Heine&
functionalities compatible with NONMEM 7.
Therefore I am not sure if PRED correction is going to be included already in
the next release.
Best regards,
Martin
From: marco.campi...@merckserono.net [mailto:marco.campi...@merckserono.net]
Sent: den 21 september 2009 17:44
To: Martin Bergstrand
comes to the wrong conclusion about a model when the original design is
based on adaptive dosing?
Best wishes,
Nick
Karlsson MO, Holford NHG. A Tutorial on Visual Predictive Checks. PAGE
17 (2008) Abstr 1434 [wwwpage-meetingorg/?abstract=1434]. 2008.
Martin Bergstrand wrote:
>
> Dear NMuse
h the concentration effect
parameter (SLOP) and Kout (5-15%). In my opinion substitution with LOQ/2 are
just as bad as omitting the BQL data (just bad in another way) for that very
example.
Kind regards,
Martin Bergstrand, MSc, PhD student
---
Pharmacome
are likely to give
unbiased results.
Best regards,
Martin Bergstrand, MSc, PhD student
---
Pharmacometrics Research Group,
Department of Pharmaceutical Biosciences,
Uppsala University
geometric means could easily be handled with Y = AV *
EXP(SEAV*EPS(1)).
Best regards,
Martin Bergstrand, MSc, PhD student
---
Pharmacometrics Research Group,
Department of Pharmaceutical Biosciences,
Uppsala University
roblem. Isn't it about time that we as the customers of bioanalytical
analysis enforce a better data reporting standard that doesn't imply non
random censoring of data?
Best regards,
Martin Bergstrand, MSc, PhD student
---
Pharmacometrics Rese
ww.page-meeting.org/pdf_assets/7002-Poster_PAGE_VPC_090618_final.pd
f).
Best regards,
Martin Bergstrand, MSc, PhD student
---
Pharmacometrics Research Group,
Department of Pharmaceutical Biosciences,
Uppsala University
Altered error model code -
IPRED=LOG(F+DFLG)
W1=THETA(5)
W2=THETA(6)
WH=THETA(7) ; Equal to 0.5 in examples out of the publication)
W=SQRT(W1*W1+(W2*(1-F/(WH+F)))**2)
Y=IPRED+W*EPS(1)
$SIMGA 1 FIX
;; ------
Best regards,
Martin Bergstra
ou resolve your problems.
Best regards,
Martin Bergstrand, MSc, PhD student
---
Pharmacometrics Research Group,
Department of Pharmaceutical Biosciences,
Uppsala University
---
P.O. Box 591
SE-751 24 Upps
2
21 4.1 0 0 3
22 3.5 0 0 3
23 8.1 0 0 3
;---
Sincerely,
David Khan and Martin Bergstrand,
Pharmacometrics Research Group,
Department of Pharmaceutical Biosciences,
Uppsala
CK(1) SAME
$OMEGA BLOCK(1) SAME
$OMEGA BLOCK(1) SAME
$OMEGA BLOCK(1) SAME
$OMEGA BLOCK(1) SAME
$OMEGA BLOCK(1) SAME
;
Best regards,
Martin Bergstrand, MSc, PhD student
---
Pharm
Dear Bei Yang,
"RATE = 0" indicates that the dose is an instantaneous bolus dose.
Best regards,
Martin Bergstrand
---
Pharmacometrics Research Group,
Department of Pharmaceutical Biosciences,
Uppsala
by the central volume of
distribution => Cmax
$TABLE ID TIME TMAX CMAX ONEHEADER NOPRINT FILE=mytab
; The individual CMAX and TMAX is found on the last row for each individual
in mytab
Kind regards,
Martin Bergstrand
---
Pharmacometr
concentration? DV
IPRE = OC4
Y= IPRE*(1+ERR(5))+ERR(6)
ENDIF
$ESTIMATION PRINT=5 METHOD=1 POSTHOC
$TABLE C ID TIME CMT EVID DV IPRE NOPRINT ONEHEADER FILE=benzopred.tab
Kind regards,
Martin Bergstrand, MSc, PhD student
fairly
strong assumptions regarding the residual error) however the variability in
tissue concentration will likely be largely dependent on variability in
processes also affecting the plasma concentrations.
Kind regards,
Martin Bergstrand, PhD
Pharmacometrics Research Group
Dept of
. Handling data below the limit of
quantification in mixed effect models. AAPS J. 2009 Jun;11(2):371-80.
Kind regards,
Martin Bergstrand, PhD
Pharmacometrics Research Group
Dept of Pharmaceutical Biosciences
Uppsala University
Sweden
martin.bergstr...@farmbio.uu.se
Visiting scientist
egards,
Martin Bergstrand, PhD
Pharmacometrics Research Group
Dept of Pharmaceutical Biosciences
Uppsala University, Sweden
martin.bergstr...@farmbio.uu.se
Visiting scientist:
Mahidol-Oxford Tropical Medicine Research Unit,
Bangkok, Thailand
Phone: +66 8 9796 7611
From: owne
. Automatic data binning for improved visual
diagnosis of pharmacometric models. J Pharmacokinet Pharmacodyn.
2011;38(6):861-71.
More about the PsN VPC functionalities can be read in this document:
http://psn.sourceforge.net/pdfdocs/npc_vpc_userguide.pdf
Kind regards,
Martin Bergstrand, PhD
achieved.
Kind regards,
Martin Bergstrand, Frank Kloprogge and the MORU Pharmacometrics group.
Mahidol-Oxford Tropical Medicine Research Unit, Bangkok, Thailand
From: owner-nmus...@globomaxnm.com [mailto:owner-nmus...@globomaxnm.com] On
Behalf Of Joachim Grevel
Sent: den 23 februari 2012
# Individual plots (3 by 3): Dependent variable v.s. time
ind.plots(xpdb, y.vals=c("DV"), layout=c(3,3), key=NULL, ylb="Dependent
variable")
Kind regards,
Martin Bergstrand, PhD
Pharmacometrics Research Group
Dept of Pharmaceutical Biosciences
Uppsala University
Sweden
martin.bergstr
?
Kind regards,
Martin Bergstrand, PhD
Pharmacometrics Research Group
Dept of Pharmaceutical Biosciences
Uppsala University
Sweden
martin.bergstr...@farmbio.uu.se
Visiting scientist:
Mahidol-Oxford Tropical Medicine Research Unit,
Bangkok, Thailand
Phone: +66 8 9796 7611
NONMEM and settings for TOL, SIGL and SIGN (see NONMEM 7 userguide).
Kind regards,
Martin Bergstrand, PhD
Pharmacometrics Research Group
Dept of Pharmaceutical Biosciences
Uppsala University
Sweden
martin.bergstr...@farmbio.uu.se
Visiting scientist:
Mahidol-Oxford Tropical
facilitate a straight forward interpretation and easy comparison to
results from other studies (with or without data following iv administration
of M3G/M6G).
Regards,
Martin Bergstrand, PhD
Pharmacometrics Research Group
Dept of Pharmaceutical Biosciences
Uppsala University
Sweden
erved
variables such as T (integrated time in $DES) and F (default model
prediction with some ADVANS). In my experience things can go wrong when you
use them outside the way it was intended, conflicts can occur.
Kind regards,
Martin Bergstrand, PhD
Pharmacometrics Research Group
De
nd THETA(9) are any positive numbers
Regards
Leonid
Original Message:
-----
From: Martin Bergstrand martin.bergstr...@farmbio.uu.se
Date: Fri, 25 May 2012 22:59:45 +0700
To: yapingz2...@gmail.com, nmusers@globomaxnm.com
Subject: RE: [NMusers] Question about handling BLOQ data with mix
state that you are “not able to get the diagnostics plots”. Do you
mean that mean that no table files are generated? If so, what error messages
are returned by NONMEM?
Kind regards,
Martin Bergstrand, PhD
Pharmacometrics Research Group
Dept of Pharmaceutical Biosciences
Uppsala University
regards,
Martin Bergstrand, PhD
Pharmacometrics Research Group
Dept of Pharmaceutical Biosciences
Uppsala University, Sweden
Postal address: Box 591, 751 24 Uppsala, Sweden
Phone +46 709 994 396
Fax + 46 18 4714003
From: owner-nmus...@globomaxnm.com [mailto:owner-nmus
Have a look on this old post.
From: owner-nmus...@globomaxnm.com [mailto:owner-nmus...@globomaxnm.com] On
Behalf Of Ribbing, Jakob
Sent: den 16 augusti 2013 14:37
To: nmusers@globomaxnm.com; robert.ba...@iconplc.com
Subject: [NMusers] Unable to post to nmusers
Dear all,
Since Monday I h
Dear Bernard and all,
This is a few of the scientific papers on that topic that I am aware of:
Vong C, Bergstrand M, Nyberg J, Karlsson MO. Rapid sample size calculations for
a defined likelihood ratio test-based power in mixed-effects models. AAPS J.
2012 Jun;14(2):176-86.
Ogungbenro, K., Aar
Dear Chenyan and Devin,
Chenyan: Nice of you quote me ;) I still stand by the old quote. In my opinion
the advantage with the pcVPC is that it is easy to diagnose if the model
accurately predicts both the central trend as well as the variability of the
data. The NPDEs on the other hand usually
than resetting them 1 by 1. See an
example in the bottom of my email.
There are multiple ways of doing this I have only described my preferred way of
doing it.
Best of luck with the modeling!
Martin Bergstrand, PhD
Pharmacometrics Research Group
Dept of Pharmaceutical Biosciences
Uppsala
MU-parameterization.
Best regards,
Martin Bergstrand, Ph.D.
Senior Consultant
Pharmetheus AB
+46(0)709 994 396
martin.bergstr...@pharmetheus.com
www.pharmetheus.com
+46(0)18 513 328
U-A Science Park, Dag Hammarskjölds v. 52b
752 37 Uppsala, Sweden
Skickat från min iPhone
11 nov. 2016 kl. 04
mixed
effects models using sampling importance resampling. J Pharmacokinet
Pharmacodyn. 2016 Oct 11.
http://link.springer.com/article/10.1007/s10928-016-9487-8
[2] SIR user guide, PsN 4.6.0:
http://psn.sourceforge.net/pdfdocs/sir_userguide.pdf
Best regards,
Martin Bergstrand, Ph.D
,
Martin Bergstrand, Ph.D.
Senior Consultant
Pharmetheus AB
*From:* owner-nmus...@globomaxnm.com [mailto:owner-nmus...@globomaxnm.com] *On
Behalf Of *Waroonrat Sukarnjanaset
*Sent:* Tuesday, June 27, 2017 10:52 AM
*To:* nmusers@globomaxnm.com
*Subject:* [NMusers] Two compartment model with fixed
file. Prior information about the appropriate model structure
should be used but it may also be necessary to include prior information
about the estimates for parameters with low identifiability given the
design of the experiment (check $PRIOR in the NONMEM used guide).
Best regards,
Martin
*At Pharmetheus, we love to talk pharmacometrics! *
Therefore, during the PAGE meeting in Montreux, Pharmetheus will offer
professional pharmacometric consulting sessions (15-30 min), free of
charge. Note that these sessions are open to everyone and independent of
any current or future plans to
lb_ij parameter becomes important to take into account.
I hope this answers you question.
Kind regards,
Martin Bergstrand, Ph.D.
Partner and Senior Consultant
Pharmetheus AB
+46(0)709 994 396
martin.bergstr...@pharmetheus.com
www.pharmetheus.com
> 28 apr. 2018 kl. 15:19 skrev Wang Ke
contact
either Martin Bergstrand at martin.bergstr...@pharmetheus.com, or Marie
Sandström (CEO) at marie.sandst...@pharmetheus.com, directly.
Best regards,
The Pharmetheus team
www.pharmetheus.com
*At Pharmetheus, we love to talk pharmacometrics! *
Therefore, during the PAGE meeting in Montreux, Pharmetheus will offer
professional pharmacometric consulting sessions (15-30 min), free of
charge. Note that these sessions are open to *everyone (including students
and post-docs)* and independe
Free Speed Consulting with Pharmetheus, again!
*T**alk** P**harmacometrics** with Pharmetheus**!*
We had a lot of applicants and good feedback from this activity at the PAGE
meeting. Therefore, during the ACoP meeting in San Diego, Pharmetheus will
once again offer professional pharmacometric co
Free speed consulting with Pharmetheus at ACoP9
*Talk Pharmacometrics with Pharmetheus!*
We had a lot of applicants and good feedback from this activity at the PAGE
meeting. Therefore, during the ACoP meeting in San Diego, Pharmetheus will
once again offer professional pharmacometric consulting
Free speed consulting with Pharmetheus at PAGE in Stockholm
Due to its popularity last year, Pharmetheus will again offer free speed
consulting at the PAGE Meeting in Stockholm, Sweden. Pharmetheus will
offer professional pharmacometric consulting sessions (~30 min), free of
charge. Note that thes
explained by the covariates.
Kind regards,
Martin Bergstrand, Ph.D.
Principal Consultant
Pharmetheus AB
+46(0)709 994 396 <+46709%C2%A0994%20396>
martin.bergstr...@pharmetheus.com
www.pharmetheus.com
+46(0)18 513 328 <+4618%20513%20328>
U-A Science Park, Dag Hammarskjölds v.
l the best,
Martin Bergstrand, Ph.D.
Principal Consultant
Pharmetheus AB
+46(0)709 994 396
martin.bergstr...@pharmetheus.com
www.pharmetheus.com
+46(0)18 513 328
U-A Science Park, Dag Hammarskjölds v. 36b
752 37 Uppsala, Sweden
This communication is confidential and is only intended for the use o
plans to use our services.
Confidentiality agreements (CDA) will be arranged ahead of the meeting for
the discussions that requires that. Read more and sign up here:
https://lnkd.in/dKgdcTa
Best regards,
The Pharmetheus Team
Martin Bergstrand,
Ph.D. Principal Consultant
Pharmetheus AB
x27;)
listVPCS <- VPCS@plotList # List of VPC plots for all strata
VPC1 <- listVPCS[[1]] # VPC for first strata
VPC2 <- listVPCS[[2]] # VPC for second strata
Kind regards,
Martin Bergstrand, Ph.D.
Principal Consultant
Pharmetheus AB
+46(0)709 994 396
martin.bergstr...@
however be sufficiently flexible to fit your data
without biasing assumptions of total dose/exposure.
Kind regards,
Martin Bergstrand, Ph.D.
Principal Consultant
Pharmetheus AB
martin.bergstr...@pharmetheus.com
www.pharmetheus.com
*This communication is confidential and is only inte
https://www.google.com/maps/search/Malandolaan+10+%0D%0A1187+HE+Amstelveen+%0D%0AThe+Netherlands?entry=gmail&source=g>
> The Netherlands
> <https://www.google.com/maps/search/Malandolaan+10+%0D%0A1187+HE+Amstelveen+%0D%0AThe+Netherlands?entry=gmail&source=g>
>
>
f the latter is when exposure-response is
studied by plotting observed PD response versus observed trough plasma
concentrations. This is already a way too long email so I will not deep
dive into that problem as well.
Best regards,
Martin Bergstrand, Ph.D.
Principal Consultant
Pharmeth
drop-out can be ignored if the frequency is
low or if there is no reason to suspect that it is directly or indirectly
connected to the dependent variable of interest.
Kind regards,
Martin Bergstrand, Ph.D.
Principal Consultant
Pharmetheus AB
martin.bergstr...@pharmetheus.com
www.pharmetheus.com
://www.mail-archive.com/nmusers@globomaxnm.com/msg03964.html
Kind regards,
Martin Bergstrand, Ph.D.
Principal Consultant
Pharmetheus AB
www.pharmetheus.com
On Wed, Aug 30, 2023 at 2:32 AM Saikumar Matcha
wrote:
>
> Hello All,
>
> I am working with PK profiles of paren
64 matches
Mail list logo
